EML4 and non-small cell lung carcinoma: In this study, we aimed to analyze the association of clinical factors and genetic factors, including ALK fusion variants and BIM polymorphism, with crizotinib PFS and overall survival (OS) in advanced EML4–ALK(+) NSCLC patients.